PLUR · Pluri Inc.

Under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), Chutzpah Holdings LP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026) Under the terms of the December 2025 SPA, the Common Warrants to purchase 625,000 Common Shares expired on June 30, 2026, as being reported in this filing.

Represents 6,284 Common Shares received upon vesting of restricted stock units ("RSUs") and 641 RSUs that are scheduled to vest within 60 days of the date hereof. Mr. Weinstein has been granted an aggregate of 10,769 RSUs under two separate equity compensation plan agreements with the Company: (i) 10,250 RSUs granted on February 25, 2025, pursuant to the Company's 2016 Equity Compensation Plan, which vest in twelve installments through February 25, 2028; and (ii) 519 RSUs granted on December 1, 2025, pursuant to the Company's 2019 Equity Compensation Plan, which are fully vested. As of the date hereof, 6,284 RSUs have vested, and an additional 641 RSUs are scheduled to vest within 60 days of the date hereof. The remaining 3,844 RSUs are unvested and subject to future vesting conditions beyond 60 days.

On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

(Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

(Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

(Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

(Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

(Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.

The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

(Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

(Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

(Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.

The Common Warrants issued under the March 2026 SPA expire 18 months from their respective issuance dates. Accordingly: (a) the warrants issued at the March 31, 2026 first closing expire on or about September 30, 2027; and (b) the warrants issued at the April 21, 2026 second closing expire on October 21, 2027. By contrast, the 625,000 Common Warrants issued under the December 2025 SPA expire on June 30, 2026.

The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

(Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

On March 24, 2026, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "March 2026 SPA") with Chutzpah Holdings LP ("CHLP"), a limited partnership beneficially owned by Mr. Alexandre Weinstein ("Mr. Weinstein"), relating to a private placement offering of: (i) 625,000 common shares of the Company, par value $0.00001 per share ("Common Shares"), and (ii) common warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and accompanying Common Warrant is $4.00. The Common Warrants are exercisable immediately at an exercise price of $4.25 per share and expire 18 months from the date of issuance. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The March 2026 SPA closed in two tranches:

(Continuation of Footnote (1) of 1/2) (a) the first closing occurred on March 31, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares; and (b) the second closing occurred on April 21, 2026, at which CHLP acquired 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares. The total gross proceeds received by the Company under the March 2026 SPA were $2,500,000. These transactions are in addition to securities previously acquired by CHLP under a Securities Purchase Agreement dated December 8, 2025 (the "December 2025 SPA"), pursuant to which CHLP acquired 625,000 Common Shares and Common Warrants to purchase 625,000 Common Shares at a combined purchase price of $4.00 per share and warrant, with closing on December 30, 2025 (as reported on the Form 4 filed on January 5, 2026).

(Continuation of Footnote (1) of 2/2) Each of the three CHLP warrant instruments contains an independent beneficial ownership limitation provision. Each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and Attribution Parties (as defined in the warrants, which include all Reporting Persons), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance (each, a "Beneficial Ownership Limitation"). Each Beneficial Ownership Limitation is a hard cap of 35% that cannot be exceeded; the Holder may decrease the limitation applicable to a particular warrant (and subsequently increase it back to a maximum of 35%) upon 61 days' prior written notice to the Company, but may not increase it above 35% under any circumstance.

The acquisition of 312,500 Common Shares and Common Warrants to purchase 312,500 Common Shares on March 31, 2026 pursuant to the first closing under the March 2026 SPA was required to be reported on a Form 4 within two business days of March 31, 2026 (i.e., by April 2, 2026). The Reporting Persons undertake to report all future transactions on a timely basis.

The March 2026 SPA defines the "Per Share Purchase Price" as $4.00, which represents the combined purchase price for one Common Share and one accompanying Common Warrant. For the purposes of this Form 4, the $4.00 combined price has been allocated equally between the Common Share ($2.00) and the Common Warrant ($2.00), consistent with the allocation methodology used in the Form 4 filed on January 5, 2026 in connection with the December 2025 SPA.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. CHL is a company organized under the laws of Jersey Islands. Mr. Weinstein indirectly owns 100% of CHL and may be deemed to beneficially own securities owned by CHL. CHLP is a limited partnership organized under the laws of Ontario, Canada. CHLP is beneficially owned by Mr. Weinstein, and Mr. Weinstein may be deemed to beneficially own securities owned by CHLP. Plantae Bioscience Ltd. ("Plantae") is a corporation organized under the laws of Israel. CHL owns approximately 78% of Plantae, and Mr. Weinstein may be deemed to indirectly beneficially own securities owned by Plantae through his 100% indirect ownership of CHL.

(Continuation of Footnote (6)) Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person. Neither the filing of this statement nor anything herein shall be deemed an admission that any Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

On December 8, 2025, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Chutzpah Holdings LP, a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company ("Mr. Weinstein"), relating to a private placement offering (the "Offering") of: (i) 625,000 common shares, par value $0.00001 per share (the "Common Shares") of the Company, and (ii) warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00.

(Continuation of Footnote 1) The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

On December 8, 2025, Pluri Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with Chutzpah Holdings LP, a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor and an existing shareholder and director of the Company ("Mr. Weinstein"), relating to a private placement offering (the "Offering") of: (i) 625,000 common shares, par value $0.00001 per share (the "Common Shares") of the Company, and (ii) warrants (the "Common Warrants") to purchase up to 625,000 Common Shares. The combined purchase price for each Common Share and Common Warrant is $4.00.

(Continuation of Footnote 1) The Common Warrants will be exercisable immediately at an exercise price of $4.25 per share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a 35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification obligations of the parties.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings LP ("CHLP"), Chutzpah Holdings Limited ("CHL"), Plantae Bioscience Ltd. ("Plantae") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.

The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

The restricted stock units ("RSUs") were approved for grant by the Board of Directors on December 4, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest equally on a monthly basis over three months following the date of grant.

The restricted stock units ("RSUs") were approved for grant by the Board of Directors on November 12, 2025, under the Company's 2019 Equity Compensation Plan. The RSUs vest over three years as follows: 50% of the RSUs will vest ratably on a quarterly basis during the first year following the date of grant, 25% will vest ratably on a quarterly basis during the second year following the date of grant, and the remaining 25% will vest ratably on a quarterly basis during the third year following the date of grant.

In connection with the issuance of common shares in a private placement transaction to Chutzpah on January 23, 2025 (previously reported by the reporting person on Form 3 filed with the Securities and Exchange Commission on February 18, 2025), the reporting person also received 26,030 prefunded warrants to purchase common shares, which, together with the 976,139 prefunded warrants to purchase common shares issued on April 25, 2025 under an amendment to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah, became exercisable following the Company's shareholders meeting on June 30, 2025. The total number of pre-funded warrants being reported after being exercised by the reporting person is 1,002,169 consisting of 976,139 plus 26,030 pre-funded warrants.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah.

In connection with the issuance of common shares in a private placement transaction to Chutzpah on January 23, 2025 (previously reported by the reporting person on Form 3 filed with the Securities and Exchange Commission on February 18, 2025), the reporting person also received 26,030 prefunded warrants to purchase common shares, which, together with the 976,139 prefunded warrants to purchase common shares issued on April 25, 2025 under an amendment to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah, became exercisable following the Company's shareholders meeting on June 30, 2025. The total number of pre-funded warrants being reported after being exercised by the reporting person is 1,002,169 consisting of 976,139 plus 26,030 pre-funded warrants.

Pre-Funded Warrants were acquired in exchange for common shares. Common Warrants were issued as part of the January 23, 2025 transaction for no additional consideration.

1,002,169 pre-funded warrants are being exercised.

On January 23, 2025, Pluri Inc. ("Pluri") entered into a Securities Purchase Agreement with Chutzpah, relating to a private placement offering of: (i) 1,383,948 common shares, par value $0.00001 per share of Pluri, (ii) pre-funded warrants to purchase up to 26,030 Common Shares, and (iii) common warrants to purchase up to 84,599 common shares. The reporting person had previously omitted filing a transaction that occurred on January 1, 2025, which was inadvertently omitted from a prior Form 4. The reporting person became aware of the omission on October 31,2025 and is reporting the transaction promptly after such discovery.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah.

The stock options are fully vested.

Represents restricted stock units that are fully vested.

Mr. Weinstein indirectly owns 77% of Plantae Bioscience Ltd. ("Plantae") and may be deemed to beneficially own securities owned by Plantae. Neither the filing of this statement nor anything herein shall be deemed an admission that Mr. Weinstein is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities owned by Plantae. Mr. Weinstein disclaims beneficial ownership of such securities covered by this statement, except to the extent of his pecuniary interest in such securities. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Mr. Weinstein indirectly owns 77% of Plantae Bioscience Ltd. ("Plantae") and may be deemed to beneficially own securities owned by Plantae. Neither the filing of this statement nor anything herein shall be deemed an admission that Mr. Weinstein is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities owned by Plantae. Mr. Weinstein disclaims beneficial ownership of such securities covered by this statement, except to the extent of his pecuniary interest in such securities. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

On April 25, 2025, the Company entered into an amendment (the "Amendment") to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah. Pursuant to the Amendment, the Company and Chutzpah agreed to exchange 976,139 Common Shares for pre-funded warrants to purchase up to 976,139 Common Shares.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person (i) states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this statement; (ii) disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities; and (iii) declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

On April 25, 2025, the Company entered into an amendment (the "Amendment") to its previously executed Securities Purchase Agreement, entered into on January 23, 2025 by the Company and Chutzpah. Pursuant to the Amendment, the Company and Chutzpah agreed to exchange 976,139 Common Shares for pre-funded warrants to purchase up to 976,139 Common Shares.

The Pre-Funded Warrants are exercisable at any time following the receipt of certain approvals from Pluri Inc.'s (the "Company") shareholders required by the applicable rules of the Nasdaq Capital Market, and remain exercisable until exercised in full.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person (i) states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this statement; (ii) disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities; and (iii) declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah. Each reporting person (i) states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any securities covered by this statement; (ii) disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities; and (iii) declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

The restricted stock units ("RSU") vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.

The number of shares beneficially owned reflects the 1-for-8 reverse stock split effected on April 1, 2024.

The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.

The restricted stock units ("RSU") vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.

The number of shares beneficially owned reflects the 1-for-8 reverse stock split effected on April 1, 2024.

Gives effect to the expiration of RSUs that did not meet the criteria for vesting.

The restricted stock units ("RSU") vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.

The number of shares beneficially owned reflects the 1-for-8 reverse stock split effected on April 1, 2024.

Gives effect to the expiration of RSUs that did not meet the criteria for vesting.

The restricted stock units ("RSU") vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.

The number of shares beneficially owned reflects the 1-for-8 reverse stock split effected on April 1, 2024.

The restricted stock units ("RSU") vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.

The restricted stock units ("RSU") vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first year following the date of grant, 25% will vest on a quarterly basis during the second year following the date of grant and the remaining 25% will vest on a quarterly basis during the third year following the date of grant.

The number of shares beneficially owned reflects the 1-for-8 reverse stock split effected on April 1, 2024.

On January 23, 2025, Pluri Inc. ("Pluri") entered into a Securities Purchase Agreement with Chutzpah, relating to a private placement offering of: (i) 1,383,948 common shares, par value $0.00001 per share of Pluri, (ii) pre-funded warrants to purchase up to 26,030 Common Shares, and (iii) common warrants to purchase up to 84,599 common shares. The reporting person had previously omitted filing a transaction that occurred on January 1, 2025, which was inadvertently omitted from a prior Form 4. The reporting person became aware of the omission on October 31,2025 and is reporting the transaction promptly after such discovery.

Pre-Funded Warrants were acquired in exchange for common shares. Common Warrants were issued as part of the January 23, 2025 transaction for no additional consideration.

The common warrants are exercisable until June 30, 2028.

This statement is jointly filed by and on behalf of each of Chutzpah Holdings Limited ("Chutzpah") and Mr. Weinstein. Mr. Weinstein indirectly owns 100% of Chutzpah and may be deemed to beneficially own securities owned by Chutzpah.

The number of shares beneficially owned reflects the 1-for-8 reverse stock split effected on April 1, 2024.

The number of shares beneficially owned reflects the 1-for-8 reverse stock split effected on April 1, 2024.

The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first anniversary of the date of grant, 25% will vest on a quarterly basis during the second anniversary of the date of grant and the remaining 25% will vest on a quarterly basis during the third anniversary of the date of grant.

The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first anniversary of the date of grant, 25% will vest on a quarterly basis during the second anniversary of the date of grant and the remaining 25% will vest on a quarterly basis during the third anniversary of the date of grant.

The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first anniversary of the date of grant, 25% will vest on a quarterly basis during the second anniversary of the date of grant and the remaining 25% will vest on a quarterly basis during the third anniversary of the date of grant

The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first anniversary of the date of grant, 25% will vest on a quarterly basis during the second anniversary of the date of grant and the remaining 25% will vest on a quarterly basis during the third anniversary of the date of grant.

The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first anniversary of the date of grant, 25% will vest on a quarterly basis during the second anniversary of the date of grant and the remaining 25% will vest on a quarterly basis during the third anniversary of the date of grant.

The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first anniversary of the date of grant, 25% will vest on a quarterly basis during the second anniversary of the date of grant and the remaining 25% will vest on a quarterly basis during the third anniversary of the date of grant.

The RSUs vest over three years as follows: 50% of RSUs will vest on a quarterly basis during the first anniversary of the date of grant, 25% will vest on a quarterly basis during the second anniversary of the date of grant and the remaining 25% will vest on a quarterly basis during the third anniversary of the date of grant.

The options shall vest quarterly over a 1 year period.

The options will be exercisable during the earlier of: (i) 7 years from the issuance of the options or (ii) 3 years from the Reporting Person ceasing to serve as a director.

The Share Options will be issued on January 1, 2023 and will vest as follows: 250,000 of the shares vest on June 30, 2023 and 250,000 of the shares vest on December 31, 2023.

The Share Options will expire three years from the later of three years from the last vesting date or the date upon which the Issuer increases its authorized share capital.

The Share Options will be issued on January 1, 2023 and will vest as follows: 250,000 of the shares vest on June 30, 2023 and 250,000 of the shares vest on December 31, 2023.

The Share Options will expire three years from the later of three years from the last vesting date or the date upon which the Issuer increases its authorized share capital.

The Share Options will vest ratably each month over a one year period and was issued to the Reporting Person in lieu of his annual salary of $375,000 in the aggregate.

The Share Options will expire three years from the later of three years from the last vesting date or the date upon which the Issuer increases its authorized share capital.

Represents common shares underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common shares.

The RSUs will vest ratably each month over a one-year period. The RSU was issued to the Reporting Person in lieu of his annual salary of $375,000 in the aggregate.